Document Actions

You are here: Home › Faculty › Professors › Thimme

Thimme

Prof. Dr.
Robert Thimme

Department of Medicine II
Medical Director
Phone: 0049-761-270-34040

www.uniklinik-freiburg.de/medizin2

CV

  • 1994 Dissertation in the department of Virology, University of Freiburg (summa cum laude)
  • 1998-2001 Postdoctoral fellowship at The Scripps Research Institute, La Jolla, CA, USA
  • 2005 Junior Professorship of Hepatitis Viral Infection, Medical Center – University of Freiburg
  • 2009 Heisenberg Professorship W2 / W3 in Hepatology, Medical Center – University of Freiburg
  • Since 2013 Medical Director, Department of Internal Medicine II, Medical Center – University of Freiburg

Focus of research

  • The research focus lies on the immune responses in hepatitis B virus (HBV) and hepatitis C virus (HCV) infection as well as hepatocellular carcinoma (HCC).
  • Coordinator HEP-CAR Consortium (Horizon 2020 Project) and Co-Speaker SFB/TRR 179 (DFG)
  • Program Spokesman Berta-Ottenstein-Program for Clinician Scientists

Selected publications

  • Wieland D, Kemming J, Schuch A, Emmerich F, Knolle P, Neuman-Haefelin C, Held W, Zehn D, Hofmann M, Thimme R. TCF1+ hepatitis C virus-specifi c CD8+ T cells are maintained after cessation of chronic antigen stimulation. Nat Commun. 2017; in press.
  • Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, Blum HE, Neumann-Haefelin C, Thimme R. Immunodominance and functional alterations of tumor-associated antigen-specifi c CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2014; 59:1415-26.
  • Seigel B, Bengsch B, Lohmann V, Bartenschlager R, Blum HE, Thimme R. Factors that determine the antiviral effi cacy of HCV-specifi c CD8+ T cells ex vivo. Gastroenterology. 2013; 144:426-36.
  • Hoh A, Heeg M, Ni Y, Schuch A, Binder B, Hennecke N, Blum HE, Nassal M, Protzer U, Hofmann M, Urban S, Thimme R. Hepatitis B Virus-Infected HepG2hNTCP Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8+ T Cells In Vitro. J Virol. 2015; 89(14):7433-8.
  • Dazert E, ... Thimme R. Loss of viral fi tness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest. 2009; 119:376-86.